Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 02, 2015 9:22 AM ET

Pharmaceuticals

Company Overview of GlaxoSmithKline Inc.

Company Overview

GlaxoSmithKline Inc., a research-based pharmaceutical company, discovers and develops medicines, vaccines, and healthcare products to customers in Canada and internationally. It offers medications for therapeutic areas and diseases, including allergies, chronic obstructive pulmonary disease, epilepsy, Parkinson's disease, asthma, depression, gastrointestinal disorders, infections, cancer, diabetes, herpes, migraine, respiratory illness, antiviral, central nervous system disorders, urology, cardiovascular, HIV/AIDS, dermatology, and oncology. The company was founded in 1902 and is based in Mississauga, Canada with regional offices in Halifax, Montreal, Toronto, and Vancouver, Canada; manufact...

7333 Mississauga Road

Mississauga, ON L5N 6L4

Canada

Founded in 1902

Phone:

905-819-3000

Fax:

905-814-2291

Key Executives for GlaxoSmithKline Inc.

President and President of Canada Pharmaceuticals
Chief Financial Officer and Vice-President of Finance
Vice President of Research & Development
Chief Medical Officer and Vice-president of Medical
Vice-President of Corporate & Legal Affairs and Corporate Secretary
Compensation as of Fiscal Year 2015.

GlaxoSmithKline Inc. Key Developments

GlaxoSmithKline and Genmab Announces Submission to US Regulatory Authorities for Arzerra (Ofatumumab) as First Line Treatment of Chronic Lymphocytic Leukemia

GlaxoSmithKline and Genmab A/S announced the submission of a supplemental Biologics License Application to the US Food and Drug Administration (FDA) for the use of Arzerra (ofatumumab) in combination with an alkylator-based therapy, to be used for treatment of CLL patients who have not received prior treatment and are inappropriate for fludarabine-based therapy. The application is based on results from an international, multi-center, randomized Phase III study of Arzerra in combination with chlorambucil versus chlorambucil alone in more than 400 patients with previously untreated CLL. Headline results from this trial were announced in May 2013 and the full study results are scheduled to be presented in two oral presentations at the 2013 American Society of Hematology annual meeting in December.

Similar Private Companies By Industry

Company Name Region
PharmaNutrients Botanical Corporation Americas
CEN Biotech, Inc. Americas
NutriCorp International Americas
Dermamed Pharmaceutical, Inc. Americas
Abamont Pharma Inc. Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GlaxoSmithKline Inc., please visit www.gsk.ca. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.